Network pharmacology combined with experimental validation revealed that TSAC exerts anti-breast cancer effects by multi-target inhibition of the Src/PI3K/EGFR signaling axis: molecular docking experiments confirmed that active components such as araloside A and elatoside L have high-affinity binding to key targets SRC, PIK3CA, and EGFR; in vitro experiments further verified that TSAC downregulates the expression of Src, PI3K, and EGFR at both gene and protein levels in a dose-dependent manner. Here, SRC is linked to breast carcinoma.